Clinical Trial Update: Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06) [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 clinical trial evaluating the efficacy and safety of roflumilast in Japanese patients aged over 40 with chronic obstructive pulmonary dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 2, Phase 3 | Status: COMPLETED